Chemiluminescence enzyme immunoassay for monitoring hepatitis c virus core protein during interferon-α2b and ribavirin therapy in patients with genotype 1 and high viral loads

Journal of Medical Virology

Volumn 77, Issue 1, 2005, Pages 77-82

  Enomoto, Masaru ^a   Nishiguchi, Shuhei ^b   Tamori, Akihiro ^a   Kohmoto, Modoka ^a   Habu, Daiki ^a   Sakaguchi, Hiroki ^a   Takeda, Tadashi ^a   Kawada, Norifumi ^a   Seki, Shuichi ^a   Shiomi, Susumu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Core protein; Enzyme immunoassay; Hepatitis C; Interferon; Ribavirin; Viral kinetics

Indexed keywords

CORE PROTEIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; DRUG MECHANISM; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CHEMILUMINESCENT MEASUREMENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; REAGENT KITS, DIAGNOSTIC; RIBAVIRIN; RNA, VIRAL; VIRAL CORE PROTEINS; VIRAL LOAD; VIREMIA;

HEPATITIS C VIRUS;

EID: 23044498570     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20416     Document Type: Article

References (27)

1. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S. 1999. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37:1802-1808.
2. Davis GL. 2002. Monitoring of viral levels during therapy of hepatitis C. Hepatology 36:8145-151.
3. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493-1499.
4. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading, and staging. Hepatology 19:1513-1520.
5. Enomoto M, Nishiguchi S, Shiomi S, Tanaka M, Yokogawa T, Fukuda K, Ueda T, Tamori A, Habu D, Takeda T, Yano Y, Otani S. 2002a. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-α treatment. Am J Gastroenterol 97:420-426.
6. Enomoto M, Nishiguchi S, Tanaka M, Fukuda K, Ueda T, Tamori A, Habu D, Takeda T, Shiomi S, Yano Y, Otani S. 2002b. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first two weeks of Interferon β treatment are predictive of long-term therapeutic response. J Interferon Cytokine Res 22:389-395.
7. Enomoto M, Nishiguchi S, Kohmoto M, Tamori A, Habu D, Takeda T, Seki S, Shiomi S. 2004. Effects of ribavirin combined with interferon-α2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 11:448-454.
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
9. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. 1986. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha Interferon. A preliminary report. N Engl J Med 315:1575-1578.
10. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. 2001. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967.
11. Kuboki M, Koide N, Kinoshita M, Ishida Y, Yamamoto S. 2000. Stimultaneous determination of viral load and genotype of hepatitis C virus by direct sequencing of the product from the Amplicor HCV Monitor v2.0 test. Hepatology 32:277A.
12. Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N Engl J Med 345:41-52.
13. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. 2000. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 38:4171-4179.
14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
15. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
16. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282:103-107.
17. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. 1995. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055.
18. Nishiguchi S, Enomoto M, Tanaka M, Fukuda K, Tamori A, Habu D, Takeda T, Shiomi S, Tanaka T, Yano Y, Otani S. 2002. Accurate prediction of response to interferon therapy by repeated measurement of hepatitis C virus core protein in patients with chronic hepatitis C. Intervirology 45:105-110.
19. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
20. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. 1998. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Swedish Study Group. Lancet 351:83-87.
21. Tanaka T, Lau JY, Mizokami M, Orito E, Tanaka E, Kiyosawa K, Yasui K, Ohta Y, Hasegawa A, Tanaka S, Kohara M. 1995. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol 23:742-745.
22. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H, Yanagihara O, Ohta Y. 1996. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 23:1330-1333.
23. Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, Alter HJ. 2000. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 32:388-393.
24. Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, Sakamoto M, Nishioji K. 1998. Dynamics of hepatitis C viremia following interferon-α administration. J Infect Dis 177:1475-1479.
25. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. 1999. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131: 174-181.
26. Zanetti AR, Romano L, Brunetto M, Colombo M, Bellati G, Tackney C. 2003. Total HCV core antigen assay: A new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol 70: 27-30.
27. Zeuzem S, Ruster B, Roth WK. 1994. Clinical evaluation of a new polymerase chain reaction assay (Amplicor™ HCV) for detection of hepatitis C virus. Z Gastroenterol 32:342-347.